[212Pb]Pb-AG1002
/ AlphaGen Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Preclinical evaluation of [212Pb]Pb-AG1002, a next generation SSTR2-targeting, non-agonist radiopharmaceutical
(AACR 2026)
- "[212Pb]Pb-AG1002 exhibits excellent radiolabeling efficiency, desirable pharmacokinetics, anti-tumor efficacy and favorable safety profile. Its robust preclinical pharmacological profiles support clinical development as a next generation α-therapeutic agent for SSTR2-positive tumors."
Preclinical • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR • SSTR2
1 to 1
Of
1
Go to page
1